Breadcrumb

Breadcrumbs

Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
2019.05.15
Daiichi Sankyo Data Presentations at 2019 ASCO Annual Meeting Highlight Depth of ADC Pipeline and P ...
PDF (177 KB)
2019.05.14
Daiichi Sankyo Announces Outcome of FDA Oncologic Drugs Advisory Committee Meeting to Review FLT3 I ...
PDF (266 KB)
2019.05.14
FDA Oncologic Drugs Advisory Committee Votes in Favor of Daiichi Sankyo’s Pexidartinib for the Trea ...
PDF (259 KB)
2019.05.08
Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response ...
PDF (181 KB)
2019.04.29
Daiichi Sankyo Announces Two Lancet Oncology Publications of Phase 1 Dose Expansion Results of [Fam ...
PDF (218 KB)
2019.04.25
Daiichi Sankyo Selects Lead Candidate Built on Zymeworks’ Azymetric™ Bispecific Platform
PDF (428 KB)
2019.04.09
Daiichi Sankyo’s EZH1/2 Dual Inhibitor Valemetostat (DS-3201) Receives SAKIGAKE Designation for Tre ...
PDF (186 KB)
2019.04.04
Daiichi Sankyo Provides Update on Ongoing FDA Review for Quizartinib for Treatment of Patients with ...
PDF (168 KB)
2019.04.03
EMA Validates Daiichi Sankyo’s Marketing Authorization Application for Pexidartinib for Treatment o ...
PDF (353 KB)
2019.03.28
Daiichi Sankyo and AstraZeneca Announce Global Development and Commercialization Collaboration for ...
PDF (188 KB)
Showing 1 - 10 of 47 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...